1-20 of 33
Thomas J. Kipps
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 7176: ROR1-dependent mutant TP53 and cyclin A1 increases, via NRF2 activation, potentially potentiate genomic instability in chronic lymphocytic leukemia cells with del(17p)

Free
Emanuela M. Ghia, Can Huang, Michael Y. Choi, George F. Widhopf, Thomas J. Kipps
Journal: Cancer Research
Cancer Res (2025) 85 (8_Supplement_1): 7176.
https://doi.org/10.1158/1538-7445.AM2025-7176
Published: 21 April 2025
View articletitled, Abstract 7176: ROR1-dependent mutant TP53 and cyclin A1 increases, via NRF2 activation, potentially potentiate genomic instability in chronic lymphocytic leukemia cells with del(17p)
Journal Articles

Abstract CT166: Similar outcomes regardless of post-randomization treatment with ibrutinib or ibrutinib + venetoclax in the phase 2 CAPTIVATE study of first-line ibrutinib + venetoclax in CLL

Free
Tanya Siddiqi, Constantine S. Tam, William G. Wierda, Paolo Ghia, Thomas J. Kipps, Alessandra Tedeschi, Eva Gonzalez-Barca, Edith Szafer-Glusman, Cathy Zhou, Lynne D. Neumayr, John N. Allan
Journal: Cancer Research
Cancer Res (2023) 83 (8_Supplement): CT166.
https://doi.org/10.1158/1538-7445.AM2023-CT166
Published: 14 April 2023
View articletitled, Abstract CT166: Similar outcomes regardless of post-randomization treatment with ibrutinib or ibrutinib + venetoclax in the phase 2 CAPTIVATE study of first-line ibrutinib + venetoclax in CLL
Journal Articles

Abstract CT021: Assessing clinical and pharmacodynamic (PD) profiles of patients (pts) with chronic lymphocytic leukemia (CLL) on ianalumab (VAY736) + ibrutinib

Free
Kerry Anne Rogers, Pearlly Yan, Ian W. Flinn, Deborah M. Stephens, Thomas J. Kipps, Sarah M. Larson, Laura Martz, Xi Chen, Huabao Wang, Ethan Hopping, Ralf Bundschuh, Alexandra Acosta, Daniela Baldoni, Anwesha Chaudhury, Jeanne Whalen, Nadia B. Hassounah, Nina Orwitz, Janghee Woo, John C. Byrd
Journal: Cancer Research
Cancer Res (2023) 83 (8_Supplement): CT021.
https://doi.org/10.1158/1538-7445.AM2023-CT021
Published: 14 April 2023
View articletitled, Abstract CT021: Assessing clinical and pharmacodynamic (PD) profiles of patients (pts) with chronic lymphocytic leukemia (CLL) on ianalumab (VAY736) + ibrutinib
Journal Articles

Abstract 1789: Pre-clinical studies to advance anti-ROR1 CAR-T cell therapy for metastatic prostate cancer

Free
Christina A.M. Jamieson, Jamillah Murtadha, Christopher S. Oh, Michelle Muldong, Evodie Koutouan, JOngwook Kim, Niloofar Etemadfard, Hae Soo Choo, Navyaa Sinha, Sanghee Lee, Christina Wu, Gabriel Pineda, Kathleen Lennon, Karl Willert, Catriona H. Jamieson, Terry Gaasterland, Rana Mckay, Christopher J. Kane, Thomas J. Kipps, Anna A. Kulidjian, Nicholas A. Cacalano, Charles Prussak
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 1789.
https://doi.org/10.1158/1538-7445.AM2023-1789
Published: 04 April 2023
View articletitled, Abstract 1789: Pre-clinical studies to advance anti-ROR1 CAR-T cell therapy for metastatic prostate cancer
Journal Articles

Abstract CT028: Fixed-duration (FD) ibrutinib (Ibr) + venetoclax (Ven) for first-line treatment of chronic lymphocytic leukemia (CLL) in patients (pts) with high-risk features: phase 2 CAPTIVATE study

Free
John N. Allan, Ian W. Flinn, Tanya Siddiqi, Paolo Ghia, Constantine S. Tam, Thomas J. Kipps, Paul M. Barr, Anna Elinder Camburn, Alessandra Tedeschi, Xavier C. Badoux, Ryan Jacobs, Bryone J. Kuss, Livio Trentin, Cathy Zhou, Anita Szoke, Maoko Naganuma, William G. Wierda
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): CT028.
https://doi.org/10.1158/1538-7445.AM2022-CT028
Published: 15 June 2022
View articletitled, Abstract CT028: Fixed-duration (FD) ibrutinib (Ibr) + venetoclax (Ven) for first-line treatment of chronic lymphocytic leukemia (CLL) in patients (pts) with high-risk features: phase 2 CAPTIVATE study
Journal Articles

Abstract 4007: Evolutionary history of transformation from chronic lymphocytic leukemia to Richter’s syndrome

Free
Erin M. Parry, Ignaty Leshchiner, Romain Guièze, Connor Johnson, Eugen Tausch, Sameer Parikh, Camilla Lemvigh, Conor Messer, Daniel Rosebrock, Filippo Utro, Chaya Levovitz, Kahn Rhrissorrakrai, Matthew Davids, Raquel A. Jacobs, Kara Slowik, Julien Broseus, Shanye Yin, Shuqiang Li, Geoff Fell, Ziao Lin, Binyamin A. Knisbacher, Neil Ruthen, Dimitri Livitz, Christof Schneider, Jialin Ma, Julian Hess, Laura Z. Rassenti, Thomas J. Kipps, Nitin Jain, William Wierda, Florence Cymbalista, Neil E. Kay, Kenneth J. Livak, Brian P. Danysh, Chip Stewart, Donna Neuberg, Jennifer R. Brown, Laxmi Parida, Stephan Stilgenbauer, Gad Getz, Catherine J. Wu
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 4007.
https://doi.org/10.1158/1538-7445.AM2022-4007
Published: 15 June 2022
View articletitled, Abstract 4007: Evolutionary history of transformation from chronic lymphocytic leukemia to Richter’s syndrome
Journal Articles

Activation of Notch and Myc Signaling via B-cell–Restricted Depletion of Dnmt3a Generates a Consistent Murine Model of Chronic Lymphocytic Leukemia

Available to Purchase
Anat Biran, Shanye Yin, Helene Kretzmer, Elisa ten Hacken, Salma Parvin, Fabienne Lucas, Mohamed Uduman, Catherine Gutierrez, Nathan Dangle, Leah Billington, Fara Faye Regis, Laura Z. Rassenti, Arman Mohammad, Gabriela Brunsting Hoffmann, Kristen Stevenson, Mei Zheng, Elizabeth Witten, Stacey M. Fernandes, Eugen Tausch, Clare Sun, Stephan Stilgenbauer, Jennifer R. Brown, Thomas J. Kipps, John C. Aster, Andreas Gnirke, Donna S. Neuberg, Anthony Letai, Lili Wang, Ruben D. Carrasco, Alexander Meissner, Catherine J. Wu
Journal: Cancer Research
Cancer Res (2021) 81 (24): 6117–6130.
https://doi.org/10.1158/0008-5472.CAN-21-1273
Published: 15 December 2021
View articletitled, Activation of Notch and Myc Signaling via B-cell–Restricted Depletion of Dnmt3a Generates a Consistent Murine Model of Chronic Lymphocytic Leukemia
Open the PDF for Activation of Notch and Myc Signaling via B-cell–Restricted Depletion of Dnmt3a Generates a Consistent Murine Model of Chronic Lymphocytic Leukemia in another window
Includes: Supplementary data
Journal Articles

Abstract 2368: miR-29-TRAF4 axis is a novel regulator of CD40 signaling in malignant B cells

Free
Sonali Sharma, Vaclav Seda, Eva Vojackova, Gabriela Mladonicka Pavlasova, Daniel Filip, Laura Ondrisova, Veronika Sandova, Lenka Kostalova, Pedro F. Zeni, Marek Borsky, Sarka Pospisilova, Medhat Shehata, Laura Z. Rassenti, Ulrich Jaeger, Michael Doubek, Matthew S. Davids, Jennifer R. Brown, Jiri Mayer, Thomas J. Kipps, Marek Mraz
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): 2368.
https://doi.org/10.1158/1538-7445.AM2021-2368
Published: 01 July 2021
View articletitled, Abstract 2368: miR-29-TRAF4 axis is a novel regulator of CD40 signaling in malignant B cells
Journal Articles

Abstract 3102: Venetoclax resistance associates with high-level expression of ROR1 and cancer stemness in chronic lymphocytic leukemia

Free
Emanuela M. Ghia, Laura Z. Rassenti, Michael Y. Choi, Miguel Quijada-Alamo, Elvin Chu, George F. Widhopf, II, Thomas J. Kipps
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): 3102.
https://doi.org/10.1158/1538-7445.AM2021-3102
Published: 01 July 2021
View articletitled, Abstract 3102: Venetoclax resistance associates with high-level expression of ROR1 and cancer stemness in chronic lymphocytic leukemia
Journal Articles

Abstract 3687: Wnt5a induces DOCK1 to complex with ROR1 and activate Rac1 leading to enhanced growth of breast cancer cells

Free
Md Kamrul Hasan, George F. Widhopf, II, Suping Zhang, Sharon M. Lam, Barbara A. Parker, Thomas J. Kipps
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): 3687.
https://doi.org/10.1158/1538-7445.AM2020-3687
Published: 15 August 2020
View articletitled, Abstract 3687: Wnt5a induces DOCK1 to complex with ROR1 and activate Rac1 leading to enhanced growth of breast cancer cells
Journal Articles

Abstract P3-10-18: Phase 1b trial of cirmtuzumab and paclitaxel for locally advanced, unresectable and metastatic breast cancer

Free
Rebecca A Shatsky, Richard B Schwab, Teresa L Helsten, Emily I Pittman, Ruifeng Chen, James B Breitmeyer, Catriona HM Jamieson, Thomas J Kipps, Barbara A Parker
Journal: Cancer Research
Cancer Res (2020) 80 (4_Supplement): P3-10-18.
https://doi.org/10.1158/1538-7445.SABCS19-P3-10-18
Published: 15 February 2020
View articletitled, Abstract P3-10-18: Phase 1b trial of cirmtuzumab and paclitaxel for locally advanced, unresectable and metastatic breast cancer
Journal Articles

Abstract 3492: Wnt5a induces ROR1 to associate with DOCK1 and promote growth of breast cancer cells

Free
Md Kamrul Hasan, Victoria Tripple, George F. Widhopf, Suping Zhang, Barbara A. Parker, Thomas J. Kipps
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 3492.
https://doi.org/10.1158/1538-7445.AM2018-3492
Published: 01 July 2018
View articletitled, Abstract 3492: Wnt5a induces ROR1 to associate with DOCK1 and promote growth of breast cancer cells
Journal Articles

Abstract CT158: Unmutated IGHV is not an adverse predictor of outcome to therapy with ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)

Free
Thomas J. Kipps, Graeme Fraser, Steven Coutre, Jennifer R. Brown, Jacqueline C. Barrientos, Paul M. Barr, John C. Byrd, Susan M. O'Brien, Marie-Sarah Dilhuydy, Stephen Devereux, Ulrich Jaeger, Carol Moreno, Paula Cramer, Stephan Stilgenbauer, Asher A. Chanan-Khan, Michelle Mahler, Mariya Salman, Mei Cheng, Anil Londhe, Joi Ninomoto, Angela Howes, Danelle James, Michael Hallek
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): CT158.
https://doi.org/10.1158/1538-7445.AM2017-CT158
Published: 01 July 2017
View articletitled, Abstract CT158: Unmutated IGHV is not an adverse predictor of outcome to therapy with ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Journal Articles

Abstract 1193: Treatment of breast cancer xenografts with paclitaxel enriches for cancer stem cells that can be targeted by a ROR1-specific antibody

Free
Suping Zhang, Grace Liu, Sam H. Lai, Han Zhang, Emanuela M. Ghia, Bing Cui, Rongrong Wu, George Widhopf, Jian Yu, Richard Schwab, Karen Messer, Barbara Parker, Thomas J. Kipps
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): 1193.
https://doi.org/10.1158/1538-7445.AM2016-1193
Published: 15 July 2016
View articletitled, Abstract 1193: Treatment of breast cancer xenografts with paclitaxel enriches for cancer stem cells that can be targeted by a ROR1-specific antibody
Journal Articles

Abstract 5485: Induction of proliferation sensitizes chronic lymphocytic leukemia cells to apoptosis mediated by the ATR inhibitor AZD6738

Free
Michael Y. Choi, Jessie-Farah Fecteau, Jeff Brown, Alan Lau, Thomas J. Kipps
Journal: Cancer Research
Cancer Res (2014) 74 (19_Supplement): 5485.
https://doi.org/10.1158/1538-7445.AM2014-5485
Published: 01 October 2014
View articletitled, Abstract 5485: Induction of proliferation sensitizes chronic lymphocytic leukemia cells to apoptosis mediated by the ATR inhibitor AZD6738
Journal Articles

Abstract 1514: An AC electrokinetic microarray device for isolation of cell circulating free nucleic acid from the blood of cancer patients

Free
Jennifer Marciniak, Avery Sonnenberg, Laura Rassenti, Emanuela Ghia, George Widhopf, Elaine Skowronski, Sareh Manouchehri, Thomas J. Kipps, Michael J. Heller, David J. Charlot, Rajaram Krishnan
Journal: Cancer Research
Cancer Res (2014) 74 (19_Supplement): 1514.
https://doi.org/10.1158/1538-7445.AM2014-1514
Published: 01 October 2014
View articletitled, Abstract 1514: An AC electrokinetic microarray device for isolation of cell circulating free nucleic acid from the blood of cancer patients
Journal Articles

Abstract 206: Depletion of ovarian cancer initiating cells by a monoclonal antibody against ROR1

Free
Suping Zhang, Bing Cui, Hsien Lai, Grace Liu, Christina Wu, George Widhopf, Rongrong Wu, Fitzgerlad Lao, Richard Schwab, Dennis Carson, Thomas J. Kipps
Journal: Cancer Research
Cancer Res (2014) 74 (19_Supplement): 206.
https://doi.org/10.1158/1538-7445.AM2014-206
Published: 01 October 2014
View articletitled, Abstract 206: Depletion of ovarian cancer initiating cells by a monoclonal antibody against ROR1
Journal Articles

Abstract C4: Targeting ROR1 inhibits epithelial-mesenchymal transition and metastasis

Free
Bing Cui, Suping Zhang, Liguang Chen, Jianqiang Yu, George F. Widhopf, II, Jessie-F Fecteau, Laura Z. Rassenti, Thomas J. Kipps
Journal: Cancer Research
Cancer Res (2013) 73 (3_Supplement): C4.
https://doi.org/10.1158/1538-7445.TIM2013-C4
Published: 01 May 2014
View articletitled, Abstract C4: Targeting ROR1 inhibits epithelial-mesenchymal transition and metastasis
Journal Articles

Targeting ROR1 Inhibits Epithelial–Mesenchymal Transition and Metastasis

Free
Bing Cui, Suping Zhang, Liguang Chen, Jianqiang Yu, George F. Widhopf, II, Jessie-F. Fecteau, Laura Z. Rassenti, Thomas J. Kipps
Journal: Cancer Research
Cancer Res (2013) 73 (12): 3649–3660.
https://doi.org/10.1158/0008-5472.CAN-12-3832
Published: 13 June 2013
View articletitled, Targeting ROR1 Inhibits Epithelial–Mesenchymal Transition and Metastasis
Open the PDF for Targeting ROR1 Inhibits Epithelial–Mesenchymal Transition and Metastasis in another window
Includes: Supplementary data
Journal Articles

Abstract 5472: Targeting chronic lymphocytic leukemia cells with a humanized monoclonal antibody specific for CD44.

Free
Suping Zhang, Christina Wu, Jessie Farrah-Fecteau, Bing Cui, Liguang Chen, Ling Zhang, Rongrong Wu, Laura Rassenti, Fitzgerald S. Lao, Stefan Weigand, Thomas J. Kipps
Journal: Cancer Research
Cancer Res (2013) 73 (8_Supplement): 5472.
https://doi.org/10.1158/1538-7445.AM2013-5472
Published: 15 April 2013
View articletitled, Abstract 5472: Targeting chronic lymphocytic leukemia cells with a humanized monoclonal antibody specific for CD44.